<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000753</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 187</org_study_id>
    <secondary_id>11162</secondary_id>
    <nct_id>NCT00000753</nct_id>
  </id_info>
  <brief_title>A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC</brief_title>
  <official_title>A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Upjohn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety, toxicity, pharmacokinetic profile, and antiretroviral activity of&#xD;
      atevirdine mesylate ( U-87201E ) in HIV-infected patients. Per 06/04/93 amendment, to also&#xD;
      evaluate the interactive effects of didanosine ( ddI ) or zalcitabine ( dideoxycytidine; ddC&#xD;
      ) with zidovudine ( AZT ) on the pharmacokinetics of U-87201E and to assess the effects of&#xD;
      the triple combination therapies on immunologic and virologic parameters.&#xD;
&#xD;
      Since the use of non-nucleoside reverse transcriptase inhibitors such as U-87201E has been&#xD;
      associated with the rapid development of resistant HIV isolates, an initial evaluation of&#xD;
      this drug in patients was made in combination with AZT. Because of the inability to detect&#xD;
      resistance after 6 weeks of combined AZT/U-87201E therapy, this protocol will initially&#xD;
      investigate U-87201E administered alone and then investigate the effect of this drug with AZT&#xD;
      and ddI or ddC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the use of non-nucleoside reverse transcriptase inhibitors such as U-87201E has been&#xD;
      associated with the rapid development of resistant HIV isolates, an initial evaluation of&#xD;
      this drug in patients was made in combination with AZT. Because of the inability to detect&#xD;
      resistance after 6 weeks of combined AZT/U-87201E therapy, this protocol will initially&#xD;
      investigate U-87201E administered alone and then investigate the effect of this drug with AZT&#xD;
      and ddI or ddC.&#xD;
&#xD;
      Ten patients are treated at each of three targeted concentration ranges of U-87201E. Patients&#xD;
      in the second cohort are enrolled immediately after patients in the first cohort are accrued;&#xD;
      patients in the third cohort are enrolled when 5 of 10 patients in the second cohort have&#xD;
      tolerated that dose for at least 4 weeks. The MTD will be the dose below that which produces&#xD;
      dose-limiting grade 3 or 4 toxicity in five out of 10 patients. At least two women and five&#xD;
      antiretroviral naive patients must be enrolled in each dose concentration range. Patients&#xD;
      receive at least 8 weeks of monotherapy with U-87201E, with possible extension to at least 24&#xD;
      weeks with the same dose of U-87201E alone or in combination with zidovudine plus either ddI&#xD;
      or ddC. Patients are followed weekly for at least 8 weeks and, if applicable, at weeks 10,&#xD;
      12, 16, 20, and 24 and monthly thereafter, up to 1 month following the last dose. Patients on&#xD;
      combination therapy will have an indwelling venous catheter inserted for the first 2 days of&#xD;
      combination therapy. Per 10/15/93 amendment, if no MTD is established with the first three&#xD;
      cohorts, then 10 additional patients will be enrolled at a fourth concentration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1995</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atevirdine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  PCP prophylaxis with pentamidine, TMP/SMX, or dapsone (if appropriate).&#xD;
&#xD;
          -  Clotrimazole troches or nystatin oral suspension for oral candidiasis.&#xD;
&#xD;
          -  Acyclovir (up to 1000 mg/day) for herpes lesions.&#xD;
&#xD;
          -  Supportive care as deemed necessary for toxicities .&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count &lt;= 500 cells/mm3.&#xD;
&#xD;
          -  No active opportunistic infections.&#xD;
&#xD;
          -  Consent of parent, guardian, or person with power of attorney, if less than 18 years&#xD;
             of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Participation of women in the study is encouraged.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Acute medical problems, including opportunistic infections (e.g., active&#xD;
             cryptococcosis, Pneumocystis carinii, herpes zoster, histoplasmosis, and CMV) or&#xD;
             nonopportunistic diseases (e.g., liver or renal disease or lymphoma).&#xD;
&#xD;
          -  Current diagnosis of malignancy for which systemic therapy would be required during&#xD;
             the study.&#xD;
&#xD;
          -  Active gastrointestinal disorders.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Investigational drugs.&#xD;
&#xD;
          -  Systemic therapy for malignancy.&#xD;
&#xD;
          -  Phenobarbital, phenytoin, ketoconazole, rifampin, rifabutin, cimetidine, beta&#xD;
             blockers, chronic antacids, antiarrhythmic agents, or other medications known to&#xD;
             affect cardiac conduction or seizure threshold.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of any cardiovascular disease, including conduction disturbances, arrhythmias&#xD;
             or atherosclerotic heart disease.&#xD;
&#xD;
          -  History of CNS disease such as seizure disorder, AIDS Dementia Complex, progressive&#xD;
             multifocal leukoencephalopathy, or any other active neurological disorder.&#xD;
&#xD;
          -  History of chronic gastrointestinal disorders such as chronic diarrhea (&gt; 4 weeks&#xD;
             duration).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral or immunomodulator agents (such as AZT, ddI, ddC, interferon, etc.)&#xD;
             within 15 days prior to study entry.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 1 month prior to study entry.&#xD;
&#xD;
          -  Prior U-87201E or other non-nucleoside reverse transcriptase inhibitors (i.e.,&#xD;
             nevirapine, TIBO, L697,661).&#xD;
&#xD;
        Present use of alcohol or illicit drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reichman R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):135-44. doi: 10.1097/00042560-199810010-00006.</citation>
    <PMID>9768622</PMID>
  </reference>
  <reference>
    <citation>Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res. 2000 Jan;45(1):47-58. doi: 10.1016/s0166-3542(99)00073-x.</citation>
    <PMID>10774589</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zalcitabine</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
    <mesh_term>Atevirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

